đ«đ·
Lys Therapeutics: Advancing neurological and vascular therapeutics through a novel mechanism of action
Lys Therapeutics is a Lyon-based Biotech company developing innovative treatments for severe neurological diseases. The company focuses on addressing the underlying mechanisms of these conditions by impeding the binding of tPA on NMDA receptors, restoring the Blood Brain Barrier (BBB).
Lys Therapeutics’ antibody, which play a critical role in conditions such as ischemic stroke and other neurodegenerative diseases, such as Alzheimer and Parkinson. The company leverages its proprietary platform to identify and develop molecules that modulate these pathways, aiming to improve clinical outcomes in patients with limited treatment options.
By integrating cutting-edge research with a focus on clinical applicability, Lys Therapeutics is advancing therapies that target the root causes of complex diseases. The company collaborates with many academic and industry partners such as, Michael J. Fox Foundation, University of Michigan, EIT Health, … to accelerate the development and delivery of its therapies to patients.
We are committed to supporting Lys Therapeutics as they advance their mission to transform the treatment of severe neurological disorders.
Their pioneering work in targeting neuro-inflammatory pathways holds significant potential to address critical unmet medical needs in conditions such as ischemic stroke and neurodegenerative diseases. By leveraging cutting-edge research and a translational approach, Lys Therapeutics is poised to deliver therapies that improve patient outcomes and redefine standards in healthcare.
We look forward to continuing our partnership with Lys Therapeutics as they progress their pipeline and bring novel therapies to patients worldwide.
We seek to customise the content to the segments we serve.
These are both fund investors and the entrepreneurs with whom we have created alliances.
We are happy to keep in touch.
